Emgality™ Approved for Migraine Prevention in Adults
2018-10-07
It's good news for Migraine patients as Eli Lilly and Company's Emgality™ (galcanezumab-gnlm) became the third new CGRP monoclonal antibody approved by the FDA for Migraine Prevention in Adults. With Emgality™ approved for Migraine prevention, patients have choices of preventive treatments were developed specifically for Migraine.Read More →